The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million ...

The bivalent vaccine is designed to defend against BA.1, an Omicron subvariant, and an early strain of the novel coronavirus. Pfizer Inc. and Moderna Inc. have been developing their versions of ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled ... shots targeting new variants like Omicron as COVID-19 becomes endemic.

Moderna has reported preliminary clinical ... it is also testing another version of the mRNA-based vaccine directed more closely at Omicron that could perform even better, with clinical data ...

Five years ago on Tuesday, the World Health Organization declared COVID-19 a global pandemic, and the impact of the virus and ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

It was exactly this week, in 2020, when COVID officially entered the mass consciousness: The NBA suddenly canceled its season ...

Wyoming Department of Health (WDH) officials are concerned with the continued active, current spread of pertussis (whooping ...

Freshfields represented Moderna, while Taylor Wessing advised BioNTech and Munich IP-firm df-mp was counsel to Pfizer.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...